ArticleJournal of the American Chemical Society2025
Design and Application of Cereblon-Recruiting Prodegraders.
Article in Journal of the American Chemical Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Generalizable Strategies for the Synthesis of Cereblon-Recruiting PROTAC Prodrugs.Angewandte Chemie (International ed. in English) · 2026Article
- Photoenzymatic Hydroalkylation Enables Streamlined Access to Aryl Glutarimide Precursors.Angewandte Chemie (International ed. in English) · 2026Article
- A Novel Paradigm for Targeting Challenging Targets: Advancing Technologies and Future Directions of Molecular Glue Degraders.Molecules (Basel, Switzerland) · 2026Review
- Chemical and Enzymatic Approaches to C-Terminal Cyclic Imide Formation.Methods in molecular biology (Clifton, N.J.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Cereblon (CRBN) is one of the most widely co-opted E3 ligase substrate receptor proteins in targeted protein degradation (TPD), and several CRBN-recruiting degraders are currently in late-stage preclinical evaluation. While the diversity of CRBN-recruiting moieties has rapidly expanded, the glutarimide ring has remained largely conserved in these ligands. Glutarimides can form during protein cleavage events via the intramolecular cyclization of glutamine within the protein backbone. Inspired by this biological mechanism, we developed CRBN-recruiting prodegraders by replacing the glutarimide in parent degraders with uncyclized glutamine analogs. Prodegraders derived from a potent, cytotoxic GSPT1 degrader exhibited
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.